Facts
- Aimee Freeman was prescribed Accutane for chronic acne and took it daily from September 27 to October 2, 1995, and from October 4 to November 20, 1995.
- Freeman alleged she developed serious conditions after use, including ulcerative colitis, inflammatory polyarthritis, nodular episcleritis, and optic nerve head drusen.
- Freeman alleged the manufacturer knew Accutane posed significant health risks but failed to disclose relevant side effects and misrepresented the drug’s safety and effectiveness to the medical community to encourage its use over alternatives.
- Freeman sued under multiple products-liability theories, including design defect, failure to warn, misrepresentation, negligence, and warranty-based claims.
- The manufacturer filed a demurrer asserting the petition failed to state a cause of action.
- The trial court dismissed with leave to amend, reasoning FDA approval insulated the manufacturer absent pleaded fraud in the FDA approval process; Freeman chose to stand on her petition.
- The trial court then dismissed the action with prejudice, and Freeman appealed.
Issues
- Whether FDA approval categorically bars state-law design-defect claims against prescription-drug manufacturers.
- Whether a plaintiff must plead “fraud on the FDA” to state a products-liability claim involving an FDA-approved prescription drug.
- Whether the petition stated plausible claims for (a) design defect, (b) inadequate warning under the learned-intermediary doctrine, and (c) misrepresentation.
Decision
- The Nebraska Supreme Court reversed the dismissal and remanded.
- The court rejected a rule that FDA approval, by itself, insulates a prescription-drug manufacturer from design-defect liability.
- The court held the plaintiff was not required to plead fraud on the FDA to proceed.
- The court held the petition adequately stated claims for design defect, inadequate warning to the prescribing physician (learned-intermediary doctrine), and misrepresentation.
- The court agreed that certain other pleaded theories were insufficiently alleged or not recognized as independently actionable as framed, including manufacturing defect and some warranty and negligence allegations.
Legal Principles
- FDA approval does not, standing alone, provide categorical immunity from state-law design-defect liability for prescription drugs.
- A products-liability plaintiff need not plead “fraud on the FDA” as an element or prerequisite to state a claim regarding an FDA-approved prescription drug.
- Prescription-drug design-defect claims may proceed under a risk-benefit framework that assesses whether foreseeable risks outweigh benefits to the extent a reasonable manufacturer would not market the drug in that form.
- Under the learned-intermediary doctrine, a prescription-drug manufacturer’s duty to warn is generally satisfied by providing adequate warnings to the prescribing physician; allegations of inadequate risk disclosure to physicians can state a claim.
- Allegations that a manufacturer made false or materially incomplete safety representations to the medical community to induce prescribing can support misrepresentation liability at the pleading stage.
- Conclusory allegations, without supporting facts, are insufficient to plead a manufacturing-defect claim; warranty and negligence theories require more than generic assertions to stand as separate claims.
Conclusion
The court reinstated the action, holding that FDA approval did not bar design-defect claims and that the plaintiff was not required to plead fraud on the FDA; the petition adequately alleged design defect, inadequate warnings to the prescribing physician, and misrepresentation, warranting further proceedings on those core theories.